EROCIN® (Erythromycin Preparations)

EROCIN® (Erythromycin Preparations)

Share this
Advertisement

EROCIN® (Erythromycin Preparations)

Composition

  • Erocin® 500 tablets: Each tablet contains Erythromycin Stearate BP equivalent to Erythromycin 500mg
  • Erocin® 250 tablets: Each tablets contains Erythromycin Stearate BP equivalent to Erythromycin 250mg
  • Erocin® Forte: Each 5ml after reconstitution contains Erythromycin Stearate USP equivalent to Erythromycin 250mg
  • Erocin® Dry mixture: Each 5ml after reconstitution contains Erythromycin Stearate USP equivalent to Erythromycin 125mg
  • Erocin® Paediatric suspension: Each 5ml after reconstitution contains Erythromycin Ethylsuccinate BP equivalent to Erythromycin 250mg
  • Erocin® Dry suspension: Each 5ml after reconstitution contains Erythromycin Ethylsuccinate BP equivalent to Erythromycin125mg.

Indications

Erocin® is indicated in the treatment of wide range of infections caused by or associated with pathogens sensitive to erythromycin therapy. It is used in conditions such as bronchitis, severe campylobacter enteritis, chancroid, diphtheria, legionnaire’s disease and other legionella infections, neonatal conjuctivitis, pertusis, pneumonia (mycoplasma and other atypical pneumonia). It is also used for the prophylaxis of surgical infections in patients undergoing bowel surgery.

Erocin® is used as an alternative to the penicillins in penicillin-allergic patients with various conditions including anthrax, the prophylaxis of endocarditis, leptospirosis, otitis media, pharyngitis, syphilis, prevention of rheumatic fever and staphylococcal skin infections.

It is also used as an alternative to the tetracyclines in patients with chlamydia infections such as epididymitis, lymphogranuloma venereum, psittacosis, Q fever, and trachoma and also used in cases of pelvic inflammatory disease and in tularaemia.

Dosage and administration

Adults and children over 8 years: For mild to moderate infections 2g daily in divided doses up to 4g daily in severe infections; 250-500mg every 6 hours or 0.5-1 g every 12 hours.

For acne vulgaris the usual dose is 250mg three times daily before meals for one to four weeks and then reduced to twice daily until improvement occurs.

Advertisement

Children aged 2 to 8 years: For mild to moderate infections 1g daily in divided doses; 250mg every 6 hours

30mg/kg/day in divided doses. For severe infections up to 50mg/kg/day in divided doses.

Infants and children up to 2 years: For mild to moderate infections 500mg daily in divided doses; 125mg every 6 hours

30mg/kg/day in divided doses. For severe infections up to 50mg/kg/day in divided doses.

Precautions, warnings and side effects

  1. The preparations should be used with caution in patients with renal and hepatic impairment and breast-feeding patients.
  2. The most frequent adverse effects occasionally associated with the preparations include nausea, vomiting, abdominal discomfort, diarrhoea, urticaria, rashes and pseudomembranous colitis.
  3. Prolonged use of the preparation may result in overgrowth of non-susceptible pathogens including fungi and in such cases appropriate medication should be instituted immediately.

Overdose

Symptoms: mainly confined to nausea, vomiting and diarrhea.

Treatment: Gastric lavage and genaral supportive measures

Properties and actions

Erocin® contain Erythromycin, a macrolide antibiotic with a bacteriostatic action against many Gram-positive and to a lesser extent some Gram-negative bacteria, as well as other organisms including mycoplasma, spirochaetes, chlamydia and rickettsia.

Erythromycin and other macrolides bind reversibly to the 60s subunit of the ribosome, resulting in blockade of the transpeptidation or translocation reactions, inhibition of protein synthesis and hence inhibition of cell growth. Its action is predominantly bacteriostatic, but high concentrations are slowly bactericidal against the more sensitive strains.

The antimicrobial activity of erythromycin is increased at moderately alkaline pH, especially in Gram-negative species, probably because of the improved cellular penetration of the non-ionised form of the drug.

Advertisement
Share this

Leave a Comment

Your email address will not be published. Required fields are marked *